M Kipnes, P Dandona, D Tripathy, JG Still, G … - Diabetes Care, 2003 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS—Eighteen patients with type 2 diabetes were
enrolled in this randomized, single-blind, placebo-controlled, three-way
crossover, dose-escalation study. A single dose of each of the following ... Cited by 52 - Related articles - BL Direct - All 6 versions
S Clement, P Dandona, JG Still, G Kosutic - Metabolism, 2004 - Elsevier An effective, orally administered insulin product would be of substantial
benefit in the treatment of patients with diabetes mellitus. This phase I/II
clinical trial was the first to investigate the safety and effectiveness of ... Cited by 43 - Related articles - All 10 versions
- ►diabetesjournals.org E Wajcberg, Y Miyazaki, C Triplitt, E … - Diabetes care, 2004 - Am Diabetes Assoc RESULTS—Fasting plasma insulin (7 μU/ml) increased to a maximum of 102, 321,
and 561 μU/ml at 60 min after all three HIM2 doses (0.125, 0.5, and 0.75 mg/kg,
respectively). A dose-related decrease in basal EGP was observed as the ... Cited by 11 - Related articles - BL Direct - All 6 versions
M Kidron, S Dinh, Y Menachem, R Abbas, B … - Diabetic Medicine, 2004 - interscience.wiley.com It is also possible that your web browser is not configured or not able to
display style sheets. In this case, although the visual presentation will be
degraded, the site should continue to be functional. We recommend using the ... Cited by 26 - Related articles - BL Direct - All 5 versions
JG Still - Diabetes Metabolism and Reviews - interscience.wiley.com NOBEX oral drug delivery technology is centered on modification of peptides,
proteins and small organic molecules by attachment of one or more amphiphilic
oligomers. Attachment of these oligomers results in stability to enzymatic ... Cited by 57 - Related articles - BL Direct - All 2 versions
HIM Treatment - Drugs of the Future, 2004 - journals.prous.com Currently available insulin preparations for the treat- ment of diabetes
mellitus are unable to mimic the pat- terns of endogenous insulin secretion, and
normo- glycemia cannot be achieved. Inadequate control of hyperglycemia, ... Related articles
D Kim, S Mudaliar, S Chinnapongse, N Chu, … - Diabetes Care, 2003 - Am Diabetes Assoc RESULTS—Inhaled insulin exhibited significantly shorter time-to-peak insulin
levels (T max 77 ± 66 vs. 193 ± 104 min, P < 0.001) and time-to-peak metabolic
effects (T GIRmax 240 ± 94 vs. 353 ± 60 min, P < 0.001) compared with ... Cited by 32 - Related articles - BL Direct - All 6 versions
HI Monoconjugate - Drugs of the Future, 2004 - journals.prous.com Currently available insulin preparations for the treatment of diabetes mellitus
are unable to mimic the patterns of endogenous insulin secretion, and
normoglycemia cannot be achieved. Inadequate control of hyperglycemia, ... Related articles
